Quanterix (QTRX) FY Conference August 13, 2025 03:30 PM ET Speaker0Hi. Welcome to the Canaccord Genuity Group Conference. I'm Kyle Mixon. I come for Life Science Tools Diagnostics for Canaccord. Really pleased to welcome you to this fireside chat with Quanterix.The company offers a really ultra sensitive protein measurement platform based on digital ELISA. With us from the company, we have Masud Tullu, CEO and Vandana Shiram, CFO. Thanks guys for joining us today. So Masud and Vandana, maybe just start out ...

A downtrend has been apparent in Quanterix Corporation (QTRX) lately with too much selling pressure. The stock has declined 24.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is ...

分组1 - Quanterix Corporation reported a quarterly loss of $0.47 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.41, and compared to a loss of $0.25 per share a year ago, indicating an earnings surprise of -14.63% [1] - The company posted revenues of $24.48 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 12.62%, and down from $34.38 million in the same quarter last year [2] - Quanterix shares have declined approximately 47.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.57 on revenues of $41.97 million, and for the current fiscal year, it is -$1.87 on revenues of $146.48 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 37% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $24.5 million, down 29% year over year due to temporary funding pauses and uncertainty in the U.S. academic and pharmaceutical end markets [15][16] - Gross profit was $11.3 million with a gross margin of 46.2%, while non-GAAP gross profit was $10.2 million with a non-GAAP gross margin of 41.8% [17][18] - Operating expenses increased to $48.4 million, up $15.2 million year over year, including significant costs related to acquisition and restructuring [19] - Adjusted EBITDA was a loss of $13.7 million compared to a loss of $4.1 million in the same quarter of the previous year [19] Business Line Data and Key Metrics Changes - Consumable revenue was $14.9 million, while instrument revenue was $2 million, with 10 instruments placed in the quarter compared to 22 in the previous year [16] - Accelerator lab revenue was $4 million, down 60%, driven by a decline in large multimillion-dollar projects from pharmaceutical customers [16] - Sales to diagnostics partners totaled $2.6 million, up from $0.7 million in the prior year period [16] Market Data and Key Metrics Changes - The customer mix was evenly split between pharma and academia, with academic sales declining 18% and pharma sales declining 38% [16] - The combined company expects to report $130 million to $135 million of revenue for 2025, with Simoa revenue expected to be $100 million to $105 million [21][22] Company Strategy and Development Direction - The company completed the transformative Equaya acquisition and is focused on sustainable double-digit revenue growth and margin improvement [6][7] - The strategic priorities include expanding the addressable market, accelerating the Simoa platform rollout, and building a foundation for an Alzheimer's diagnostic franchise [10][11][13] - The company aims to achieve approximately $85 million in synergy savings and cost reductions by 2026, with 75% of these expense reductions already implemented [7][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged temporary headwinds in academic funding and biopharma spending but expressed confidence in the long-term growth potential of proteomics [6][9] - The company is committed to achieving cash flow breakeven in 2026, even amidst challenging market conditions, and has already exceeded synergy expectations [24][25] Other Important Information - The company ended the quarter with $263.8 million in cash and equivalents, with adjusted cash usage improving by 49% year over year [20] - Akoya generated $18.2 million in Q2, contributing to the combined company's revenue outlook [21] Q&A Session Summary Question: Insights on Accelerator business and clinical trials - The Accelerator business grew approximately 40% year on year, with a net increase in customers, although project sizes are smaller than last year [29][30] Question: Academic funding outlook and customer confidence - There is strong resiliency in the consumables franchise, with approximately $100 million in consumables revenue, indicating potential positivity in academic funding [31][32] Question: Cost actions and long-term growth - The integration has focused on operating as one company, realizing significant synergies in operations and maintaining a focus on customer service while addressing cost structures [35][36]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________ FORM 10-Q _________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 __ ...

Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2025 BILLERICA, Mass. – August 7, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. "Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market," said Ma ...

Financial Performance & Outlook - Q2 2025 revenue decreased by 29% to $24.5 million compared to $34.4 million in Q2 2024[17] - GAAP gross margin decreased to 46.2% in Q2 2025 from 64.7% in Q2 2024[17] - The company is aiming for cash flow breakeven in 2026[14] - Full year 2025 revenue guidance is $130 to $135 million, including a $30 million contribution from Spatial[21] - Adjusted cash usage for the full year 2025 is projected to be $34 to $38 million[23] Cost Reduction & Synergies - The company has implemented $64 million of the total $85 million cost reduction plan[15] - Synergy and cost actions are expected to reach $85 million[13] - $3 million cost reduction realized in Q2 2025[14] Strategic Initiatives - The company completed the acquisition of Akoya, enabling new protein biomarker measurements[10, 11] - Strategic investments are being made in new assays, the Simoa One platform, and Alzheimer's diagnostics[12] - The company is building a $100 million high-margin consumables business[13] Alzheimer's Disease Testing - Development of LucentAD multi-marker test for Alzheimer's disease with 90% sensitivity, specificity, and accuracy[16] - Anticipated submission for Single-Site IVD by the end of 2025[16] - Medicare pricing anticipated in 2025 at $897 per test proposed[16]

Core Viewpoint - Quanterix has completed the acquisition of Akoya Biosciences through a stock and cash transaction, aiming for technological complementarity and market expansion [1]. Group 1: Acquisition Details - On July 8, 2025, Quanterix announced the completion of the acquisition of Akoya Biosciences, issuing 78 million shares of common stock and paying $20 million in cash [2]. - The acquisition was structured as 1 share of Akoya stock exchanged for 0.1461 shares of Quanterix stock plus $0.38 in cash [2]. - The acquisition process began in early 2025, with initial terms proposing 1 share of Akoya stock for 0.318 shares of Quanterix stock [3]. Group 2: Strategic Objectives - The acquisition aims to combine Akoya's spatial biology with Quanterix's ultra-sensitive protein detection technology, creating technological synergies [3]. - The deal is expected to expand application areas from neurology to oncology, leveraging Akoya's partnerships to drive product entry into clinical markets [3]. - The transaction is projected to generate approximately $40 million in annual cost synergies, with $20 million expected to be realized in the first year post-transaction [3]. Group 3: Company Background - Quanterix Corporation (NASDAQ: QTRX) is a life sciences company based in Billerica, Massachusetts, founded in 2007, focusing on ultra-sensitive biomarker detection [4]. - The company's core innovation is the Simoa® (Single Molecule Array) technology, which allows for the detection of proteins and nucleic acids in blood, plasma, or serum at femtogram per milliliter sensitivity [4]. - The merger and technology integration will expand Quanterix's business from single protein detection to spatial biology, potentially enhancing its role in multi-omics research and personalized medicine [4].

Financial Data and Key Metrics Changes - The company reported record consumables revenue exceeding $18 million, reflecting strong product development efforts and an expanded assay portfolio [5][6] - The Accelerator services business grew by 36% year-on-year, although some pharma projects were pushed to later quarters due to market conditions [7][8] - Overall, the company expects to stabilize and return to a pace of clinical trials and preclinical work as the biopharma market stabilizes [8][10] Business Line Data and Key Metrics Changes - Consumables revenue showed significant growth, driven by the introduction of over 20 new assays last year and a similar cadence expected this year [5][6] - The instruments segment remained stable year-over-year, indicating consistent demand [6] - The Accelerator Lab has become a significant revenue source, contributing approximately 30% of the business and showing strong growth in clinical and market adoption [18][20] Market Data and Key Metrics Changes - The company has about 20-22% exposure to the government end market, with some paralysis in customer decisions due to uncertainties in grant funding [12][13] - The academic research market is experiencing pressure, but the company is finding ways to mitigate this through services and consumables [12][13] Company Strategy and Development Direction - The company aims to expand its addressable market from $1 billion in neurology to $5 billion by including immunology and immuno-oncology [42][43] - The introduction of the SYM-one platform is expected to enhance sensitivity and complexity in immunology and oncology, broadening the company's market reach [30][34] - The company is focused on maintaining R&D investments while implementing cost-saving measures, ensuring continued innovation in key areas [39][40] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are delays in project decisions, there have been no cancellations, indicating a cautious but positive outlook for future projects [9][10] - The company is optimistic about the growth potential in the liquid biopsy market, emphasizing the importance of protein biomarkers alongside DNA [44][46] - Management believes that the adoption of blood-based biomarkers for Alzheimer's will increase as therapy adoption improves, creating a synergistic effect [54][56] Other Important Information - The company is preparing for the launch of the SYM-one platform, which will be compatible with over 20,000 flow cytometers, significantly increasing its market reach [32][36] - The company has initiated a cost savings program targeting $55 million in savings by the end of 2026, focusing on G&A and volume-related costs [38][39] Q&A Session Summary Question: Can you discuss the recent Q1 results and the impact of academic funding concerns? - The company reported strong consumables growth but noted that academic funding concerns have affected the outlook for the Accelerator Lab [4][5] Question: What is the exposure to the government end market and the impact of NIH spending cuts? - Approximately 20-22% of customers have NIH exposure, and while there is some paralysis in decision-making, the company is finding ways to support these customers [12][13] Question: How does the Accelerator Lab contribute to the business? - The Accelerator Lab has evolved into a significant revenue source, providing stability and repeat business, especially in a CapEx constrained environment [18][20] Question: What are the expectations for the SYM-one platform launch? - The SYM-one platform is expected to enhance sensitivity and complexity in immunology and oncology, with a launch planned before the end of the year [30][34] Question: How does the company plan to balance cost savings with R&D investments? - The company is implementing cost savings primarily in G&A and volume-related areas while maintaining strong investments in R&D and innovation [39][40] Question: What is the rationale behind the Akoya acquisition? - The acquisition aims to increase the addressable market and achieve synergies through a unified operating line and commercial team, targeting profitability by 2026 [42][43]

Core Viewpoint - Kent Lake PR LLC, holding approximately 6.9% of Quanterix Corporation's outstanding common stock, criticizes Quanterix's pursuit of Akoya Biosciences, particularly in light of Akoya's unsolicited all-cash offer of $1.40 per share, which represents a 22% premium over Akoya's 30-day VWAP and Quanterix's implied offer price under the Amended Merger Agreement [1][2]. Group 1: Merger Agreement and Financial Implications - Quanterix's Amended Merger Agreement commits the company to pay $20 million in cash and issue 8.4 million new shares, which is viewed as a misguided approach to acquiring Akoya [2]. - Quanterix's current share price of approximately $4.75 reflects a significant discount to its net cash position, indicating investor concerns over potential value destruction from the merger [3]. - The enterprise value of Quanterix is reported to be negative $80 million, raising questions about the viability of the merger and the company's financial health [7]. Group 2: Shareholder Sentiment and Board Actions - The Quanterix Board is urged to reconsider its strategy regarding the Akoya acquisition, as pursuing an alternative proposal could jeopardize the company's balance sheet [4][6]. - There is a strong indication that Quanterix shareholders do not support the merger terms, as expressed by Dr. Toloue, who noted that major stockholders have concerns about the deteriorating market conditions [9]. - Kent Lake PR calls for the Quanterix Board to allow Akoya to accept a superior proposal without increasing the purchase consideration, emphasizing that any increase would breach fiduciary duty [8]. Group 3: Future Projections and Risks - Dr. Toloue's projections for the combined company to break even in 2026 are viewed skeptically, as the companies are currently burning over $80 million, and achieving promised synergies of $55 million would still leave a deficit [5]. - The anticipated NIH budget cuts in 2026 further complicate the outlook for significant revenue growth, making reliance on such projections risky [5].